Our mission is to reduce the burden of
bacterial infections on humanity and
animals in “the post-antibiotic” era.
Vision: BacVax employs an innovative “omics” approach, termed the Bacterial Vaccine Polypeptide (“BVP”) platform (applicable to any organism) to design vaccines that prevent bacterial infections. BacVax will use the BVP platform to create a pipeline of new vaccines for select human and animal diseases. BacVax will engage partners, on a per product basis, in licensing agreements for product development, clinical studies, regulatory approval, and marketing.
The technology reflected in the patent applications is the result of decades of research enabled by recent developments in bioinformatics and related technologies. One patent application reflects the platform innovation while the other patent application reflects the discovery of peptides incorporated into the nontypeable H. influenzae product. The University of Arizona took the lead in administering the patent applications on behalf of Phoenix Children’s Hospital (“PCH”) and the University of Oklahoma. BacVax entered into an Exclusive Patent License Agreement with the University of Arizona, Tech Launch Arizona, for the technologies reflected in both patent applications. BacVax’s license includes all rights associated with Patent Cooperation Treaty (“PCT”) applications PCT/US16/36180 and PCT/US19/56298.
Terrence L. Stull, M.D., is trained in Pediatric Infectious Diseases and has decades of research on bacteria, specifically H. influenzae. Dr. Stull is the past Chairman of the Department of Pediatrics at the University of Oklahoma Health Sciences Center and most recently was the Senior Vice-President of Research at Phoenix Children’s Hospital. He is also a professor at the University of Arizona College of Medicine Phoenix, where he oversaw molecular genetics vaccine research.
Dr. Stull’s colleagues at BacVax include Paul Whitby, Ph.D., Huda Mussa, Ph.D., and Bryan Cole. Dr. Stull and his colleagues are scientists primarily responsible for the discoveries set forth in the patent applications during their work at the University of Oklahoma and PCH. The company leased laboratory space in the newly constructed Phoenix Biomedical Campus (aka the “Wexford Building”), where the team is applying its proprietary approach to laboratory and bioinformatics research.